These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4976352)

  • 61. [Clinical-experience with thiotepa in the treatment of bladder cancer].
    Gallo FJ; Menéndez-Ondina L; Matallana A; Bonilla JA; Serrano E; Carballido JA; Mendoza A
    Actas Urol Esp; 1978; 2(5):237-40. PubMed ID: 103371
    [No Abstract]   [Full Text] [Related]  

  • 62. Intractable bladder hemorrhage requiring cystectomy after use of intravesical thiotepa.
    Treible DP; Skinner D; Kasimain D; Friedman NB; Kern WH
    Urology; 1987 Dec; 30(6):568-70. PubMed ID: 3120389
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Directed chemotherapy in superficial carcinoma of the bladder conditioned by the knowledge of recurrence factors].
    Oliver F; Llopis B; Vera C; Domínguez C; Vidal J; Gallego J; Jiménez JF
    Actas Urol Esp; 1989; 13(1):41-3. PubMed ID: 2496584
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical and experimental projects on chemotherapy of bladder tumours.
    Pavone-Macaluso M; Rausa L; Gebbia N; Caramia G; Rizzo FP; Arena E; Tessitore V; Vecchioni M
    S Afr Med J; 1974 Mar; 48(15):631-6. PubMed ID: 4378338
    [No Abstract]   [Full Text] [Related]  

  • 65. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.
    Byar D; Blackard C
    Urology; 1977 Dec; 10(6):556-61. PubMed ID: 414402
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
    Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
    J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.
    Zincke H; Utz DC; Taylor WF; Myers RP; Leary FJ
    J Urol; 1983 Mar; 129(3):505-9. PubMed ID: 6403716
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Usual harmlessness of endovesical instillations of thio-tepa].
    des Roseaux M; Vacant J; Beurton D; Cukier J
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):485-7. PubMed ID: 4216647
    [No Abstract]   [Full Text] [Related]  

  • 69. The value of thiotepa in the treatment of superficial bladder tumors.
    Akdaş A; Kirkali Z; Sengör F; Ilker Y; Taşar C
    Turk J Pediatr; 1984; 26(1-4):243-50. PubMed ID: 6443167
    [No Abstract]   [Full Text] [Related]  

  • 70. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.
    Dalesio O; Schulman CC; Sylvester R; De Pauw M; Robinson M; Denis L; Smith P; Viggiano G
    J Urol; 1983 Apr; 129(4):730-3. PubMed ID: 6405056
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Local application of THIO-TEPA in the prevention of recurrent papillary carcinoma of the bladder.
    Csellár M; Csontai A
    Int Urol Nephrol; 1979; 11(1):39-44. PubMed ID: 112079
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.
    Prout GR; Koontz WW; Coombs LJ; Hawkins IR; Friedell GH
    J Urol; 1983 Oct; 130(4):677-80. PubMed ID: 6411939
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Thio-tepa in the prevention of recurrences of papillary bladder tumors].
    Kierfeld G; Mellin P
    Z Urol Nephrol; 1973 Aug; 66(8):569-72. PubMed ID: 4204011
    [No Abstract]   [Full Text] [Related]  

  • 74. [Progress in the internist treatment of bladder tumors].
    Baumgartner G
    Wien Med Wochenschr; 1982 Jul; 132(13-14):305-12. PubMed ID: 6814073
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Management of superficial bladder carcinoma with BCG. Long term follow-up.
    Martínez-Piñeiro JA
    Prog Clin Biol Res; 1984; 162B():335-45. PubMed ID: 6438642
    [No Abstract]   [Full Text] [Related]  

  • 76. [Reoperation for severe hematuria following chemotherapy for bladder papillomatosis previously treated by surgery and cobalt therapy].
    Sauvage R
    Acta Urol Belg; 1981 Jan; 49(1):36-43. PubMed ID: 6782845
    [No Abstract]   [Full Text] [Related]  

  • 77. [BCG in superficial carcinoma of the bladder. Authors' experience].
    Bordalba Gómez JR; Muñoz Segui J; Aguilo F; Gil Vernet A; Vigues F; Lopez Costea MA; Serrallach N
    Actas Urol Esp; 1992 Jun; 16(6):443-5. PubMed ID: 1509911
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chemoprophylaxis of bladder cancer recurrence: immunological aspects.
    Corrado F; Lalanne G; Pizza GC
    Panminerva Med; 1975; 17(7-8):253-8. PubMed ID: 808781
    [No Abstract]   [Full Text] [Related]  

  • 79. [Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor--prophylactic and therapeutic instillation for carcinoma in situ].
    Shichiri Y; Kanba T; Yoshida S; Arai Y
    Hinyokika Kiyo; 1995 May; 41(5):359-64. PubMed ID: 7598036
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Personal experience with treatment of vesical tumors by instillation of a cytostatic (preliminary report)].
    Wainberg S; Budich M; Paredes R; Leisner M
    Rev Argent Urol Nefrol; 1969; 38(10):430-2. PubMed ID: 4989830
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.